Update on the development of a novel dry cow therapy using a bismuth-based intramammary teat seal in combination with the bacteriocin lacticin 3147
1 Teagasc, Dairy Products Research Centre, Moorepark, Fermoy, Co Cork
2 Teagasc, Dairy Production Research Centre, Moorepark, Fermoy, Co Cork
3 Alimentary Pharmabiotic Centre, University College Cork
4 Department of Microbiology, University College Cork
Irish Veterinary Journal 2004, 57:652-656 doi:10.1186/2046-0481-57-11-652Published: 1 November 2004
Public concerns over the widespread prophylactic use of antibiotics have led to a search for alternatives to dry cow therapy for the prevention of intramammary infections. A popular alternative is to infuse a teat seal at drying-off. The teat seal is a viscous non-antibiotic formulation and when it is infused into the teat canal and the teat sinus it forms an internal seal that provides a physical barrier to invasion by mastitis-causing pathogens. Enhancement of teat seal formulations may be achieved using non-antibiotic additives such as bacteriocins, potent proteins produced by some bacteria that have the ability to kill other microorganisms. This paper traces the history of investigations at Moorepark Research Centre into the efficacy of teat seal plus lacticin 3147, a bacteriocin produced by Lactococcus lactis DPC3147, in the prevention of intramammary infections in dry cows. Indications from on-going investigations are that a dry cow formulation combining the two products has considerable potential as a non-antibiotic prophylactic product.